Next Article in Journal
Cell Line Secretome and Tumor Tissue Proteome Markers for Early Detection of Colorectal Cancer: A Systematic Review
Previous Article in Journal
Current and Prospective Protein Biomarkers of Lung Cancer

Pancreatic Cancer Chemoresistance to Gemcitabine

by 1,2,* and 2,3
Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, PO Box 1057 Blindern, 0316 Oslo, Norway
Department of Hepato-Pancreato-Biliary Surgery, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Cancers 2017, 9(11), 157;
Received: 2 November 2017 / Revised: 11 November 2017 / Accepted: 14 November 2017 / Published: 16 November 2017
Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer, ranks among the leading causes of cancer-related deaths in the Western world due to disease presentation at an advanced stage, early metastasis and generally a very limited response to chemotherapy or radiotherapy. Gemcitabine remains a cornerstone of PDAC treatment in all stages of the disease despite suboptimal clinical effects primarily caused by molecular mechanisms limiting its cellular uptake and activation and overall efficacy, as well as the development of chemoresistance within weeks of treatment initiation. To circumvent gemcitabine resistance in PDAC, several novel therapeutic approaches, including chemical modifications of the gemcitabine molecule generating numerous new prodrugs, as well as new entrapment designs of gemcitabine in colloidal systems such as nanoparticles and liposomes, are currently being investigated. Many of these approaches are reported to be more efficient than the parent gemcitabine molecule when tested in cellular systems and in vivo in murine tumor model systems; however, although promising, their translation to clinical use is still in a very early phase. This review discusses gemcitabine metabolism, activation and chemoresistance entities in the gemcitabine cytotoxicity pathway and provides an overview of approaches to override chemoresistance in pancreatic cancer. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; gemcitabine; chemoresistance; tumor stroma pancreatic ductal adenocarcinoma; gemcitabine; chemoresistance; tumor stroma
Show Figures

Figure 1

MDPI and ACS Style

Amrutkar, M.; Gladhaug, I.P. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers 2017, 9, 157.

AMA Style

Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers. 2017; 9(11):157.

Chicago/Turabian Style

Amrutkar, Manoj, and Ivar P. Gladhaug. 2017. "Pancreatic Cancer Chemoresistance to Gemcitabine" Cancers 9, no. 11: 157.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop